HER2 in prostate cancer--a viable target or innocent bystander?
Scher
H I
HI
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology*; D003584:Cytological Techniques / Q000379:methods*; D003937:Diagnosis, Differential; D018450:Disease Progression; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D018734:Genes, erbB-2 / Q000235:genetics; D020662:Guanine Nucleotide Exchange Factors / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D019394:Ki-67 Antigen / Q000097:blood; D008297:Male; D009919:Orchiectomy; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000187:drug effects / Q000378:metabolism*; D000068878:Trastuzumab; D044767:Ubiquitin-Protein Ligases; D015854:Up-Regulation / Q000187:drug effects
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D020662:Guanine Nucleotide Exchange Factors; D019394:Ki-67 Antigen; D017430:Prostate-Specific Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; D044767:Ubiquitin-Protein Ligases; C118566:HERC2 protein, human